| Trial ID: | L4822 |
| Source ID: | NCT01421355
|
| Associated Drug: |
Atazanavir
|
| Title: |
A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01421355/results
|
| Conditions: |
Type 1 Diabetes Mellitus
|
| Interventions: |
DRUG: Atazanavir
|
| Outcome Measures: |
Primary: Change in Brachial Artery Diameter, The primary endpoint is the difference in the change in brachial artery diameter in response to a flow stimulus at visit 2 and 3. It is anticipated that a response will occur following atazanavir therapy compared with baseline. The principal secondary endpoints are the serum measures of oxidant stress and antioxidant capacity., Day 0 and Day 4 |
|
| Sponsor/Collaborators: |
Sponsor: Brigham and Women's Hospital | Collaborators: National Institutes of Health (NIH)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
15
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose:
|
| Start Date: |
2012-05
|
| Completion Date: |
2014-02
|
| Results First Posted: |
2014-07-21
|
| Last Update Posted: |
2014-07-21
|
| Locations: |
Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01421355
|
